7-18-2017

Protection of Cells from Degeneration and Treatment of Geographic Atrophy

Jayakrishna Ambati
University of Kentucky, jayakrishna.ambati@uky.edu

Click here to let us know how access to this document benefits you.

Follow this and additional works at: https://uknowledge.uky.edu/ophthalmology_patents

Part of the Ophthalmology Commons

Recommended Citation
https://uknowledge.uky.edu/ophthalmology_patents/23

This Patent is brought to you for free and open access by the Ophthalmology and Visual Science at UKnowledge. It has been accepted for inclusion in Ophthalmology and Visual Science Faculty Patents by an authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.

WO WO 2009015107 Al * 1/2009


Doyle et al. (2012) NLRP3 has a protective role in age-related macular degeneration. J Immunol 175, 7623-7634.


Hirano et al., “IL-18 is not therapeutic for neovascular age-related macular degeneration”, Nature Medicine, doi:10.1038/nm.3671.


Primary Examiner — Neil P Hammell

(74) Attorney, Agent, or Firm — Stites & Harbison PLLC; Mandy Wilson Decker; Sean Ritchie

(57) ABSTRACT

Therapeutic uses P2X inhibition and inhibition of IRAK1 and/or IRAK4, methods protecting a cell, and screening methods for identifying inhibitors are described herein.

2 Claims, 24 Drawing Sheets
OTHER PUBLICATIONS


Li, et al., Nicotine Reduces TNF-α Expression Through a a7 nAChR/MyD88/NF-κB Pathway in IHE16 Airway Epithelial Cells, Cell Physiol Biochem 2011;27:651-661.


Jaffe, et al., Randomized Trial to Evaluate Tansodiporone in Geographic Atrophy Secondary to Age-Related Macular Degeneration: The GATE Study, 2015 The Authors. Published by Elsevier Inc., pp. 1-9.


References Cited

OTHER PUBLICATIONS


Vickers, et al., Modification of MyD88 mRNA Splicing and Inhibition of IL-1 Signaling in Cell Culture and in Mice with a 2'-O-Methoxyethyl-Modified Oligonucleotide, The Journal of Immunology, Nov. 5, 2015, pp. 3652-3661.


Debets, et al., IL-18 Receptors, Their Role in Ligand Binding and Function: Anti-IL-1RaChPL Antibody, a Potent Antagonist of IL-18, The Journal of Immunology, 2000, pp. 4950-4956.


* cited by examiner
Figure 1
Figure 1, cont'd
Figure 2, cont’d
Figure 2, Cont'd
Figure 3
Figure 3, Cont’d
Figure 4
Figure 5
Figure 5, Cont'd
Figure 6
Figure 6, Cont’d
Figure 7
Figure 7, Cont'd
Figure 8
Figure 8, Cont'd
Figure 9
Figure 9, Cont'd
Figure 10

A

Control AS  DICER1 AS

Caspalux

Bright-field

Overlay

(1.0)  (1.7)

B

DICER1 AS

Control AS  Alu AS

Caspalux

Bright-field

Overlay

(1.0)  (0.1)
Figure 11
**Alu RNA**

<table>
<thead>
<tr>
<th></th>
<th>Vehicle</th>
<th>IRAK1/4 inhibitor 1.5 µg</th>
<th>IRAK 1/4 inhibitor 15 µg</th>
</tr>
</thead>
</table>

Figure 13

![Alu RNA images]

**Figure 14**

Human RPE cell viability (%)

- **pNull**: 100
- **pAlu**: 80
- **IRAKs i**: 140

![Bar chart showing cell viability]
Figure 15

Figure 16
Figure 17

Figure 18
PROTECTION OF CELLS FROM DEGENERATION AND TREATMENT OF GEOGRAPHIC ATROPHY

RELATED APPLICATIONS

This application claims priority from U.S. Provisional Application Ser. No. 61/586,427 filed Jan. 13, 2012, the entire disclosure of which is incorporated herein by this reference.

GOVERNMENT INTEREST

This invention was made with government support under Grant No. EY022238-01 awarded by the National Institutes of Health.

TECHNICAL FIELD

The presently-disclosed subject matter relates to therapeutic uses of inflammasome inhibition, P2X₇ inhibition, and inhibition of IRAK1 and/or IRAK4, methods protecting a cell, and screening methods for identifying inhibitors.

INTRODUCTION

Age-related macular degeneration (AMD) is a devastating disease that affects the vision of tens of millions of individuals worldwide (Smith et al., 2001). AMD is characterized by dysfunction and degeneration of the retinal pigmented epithelium (RPE), a highly specialized monolayer of cells that is interposed between the retinal photoreceptors and the choroidal capillaries (Ambati et al., 2003). RPE dysfunction can lead to anatomical and functional disruption of both the photoreceptors and the choroidal vasculature (Blaauwgeers et al., 1999; Lopez et al., 1996; McLeod et al., 2008). These tissue architecture disruptions lead to atrophic or neovascular disease phenotypes. Although there are multiple approved therapies for the neovascular form of AMD (Ferrara, 2010), there is no effective treatment for the far more common atrophic form of the disease. GA, the advanced stage of atrophic AMD, is characterized by degeneration and death of the RPE, and is the leading cause of untreatable vision loss.

Recently, it was shown that a dramatic and specific reduction of the RNase Dicer1 results in accumulation of Alu RNA transcripts in the RPE of human eyes with GA (Kaneko et al., 2011; International Patent Application No. PCT/US11/38753, Ambati). These repetitive element transcripts, which are non-coding RNAs expressed by the highly abundant Alu retrotransposon (Batzer and Deininger, 2002), induce human RPE cell death and RPE degeneration in mice. Dicer1 deficit in GA RPE was not a generic cell death response because Dicer1 expression was not dysregulated in a variety of other retinal diseases. Likewise, Alu RNA accumulation did not represent generalized retrotransposon activation due to a stress response in dying cells because several other retrotransposons were not elevated in GA RPE, Dicer1 is central in the biogenesis of mature microRNAs (Bernstein et al., 2001). Yet, intriguingly, following Dicer1 deficit, the accumulation of Alu RNA transcripts and the lack of mature microRNAs was the critical determinant of RPE cell viability (Kaneko et al., 2011). Moreover, other RNAs of similar length such as 7S/L RNA, transfer RNA, and primary microRNAs do not induce RPE degeneration (Kaneko et al., 2011), ruling out a non-specific toxicity of excess, highly structured RNA. Still, the precise mechanisms of Alu RNA-induced cytotoxicity are unknown.

Although the retina is a tissue exceptional for its immune privilege (Streilein, 2003), its hypersensitive response to exogenous insults mediated by innate immune sensors can result in profound inflammation. The three major classes of innate immune receptors include the toll-like receptors (TLRs), retinoic acid inducible gene 1 (RIG-I)-like helicases, and nucleotide-binding domain and leucine-rich-repeat-containing (NLR) proteins (Akira et al., 2006). Numerous innate immune receptors have been identified in the RPE (Kumar et al., 2004), and a variety of exogenous substances can induce retinal inflammation (Allensworth et al., 2011; Kleinnman et al., 2011). However, it is not known whether this surveillance machinery recognizes or responds to host endogenous RNAs. As described herein, the present inventor explored the concept that innate immune machinery, whose canonical function is the detection of pathogen associated molecular patterns and other moieties from foreign organisms, might also recognize cytotoxic Alu RNA.

As described herein, it was shown that Alu transcripts can hijack innate immunity machinery to induce RPE cell death. Surprisingly, the data set forth herein show that Dicer1 deficit or Alu RNA activates the NLRP3 inflammasome in a MyD88-dependent, but TLR-independent manner. Until now, NLRP3 inflammasome activation in vivo has been largely restricted to immune cells, although the findings open the possibility that NLRP3 inflammasome activity may be more widespread than previously thought, as reflected by examples in cell culture studies of keratinocytes (Feldmeyer et al., 2007; Keller et al., 2008). The findings disclosed herein also broaden the scope of Dicer1 function beyond microRNA biogenesis, and identify its role as a guardian against the aberrant overexpression of toxic retrotransposon genetic elements that comprise roughly 50% of the human genome (Lander et al., 2001). The findings present a novel self-recognition immune response, whereby endogenous non-coding RNA-induced NLRP3 inflammasome activation results from Dicer1 deficiency in a non-immune cell. Also proposed herein are unique targets for protecting RPE cells against cell death, including P2X7 activation and IRAK-1/4.

SUMMARY

The presently-disclosed subject matter meets some or all of the above-identified needs, as will become evident to those of ordinary skill in the art after a study of information provided in this document.

This Summary describes several embodiments of the presently-disclosed subject matter, and in many cases lists variations and permutations of these embodiments. This Summary is merely exemplary of the numerous and varied embodiments. Mention of one or more representative features of a given embodiment is likewise exemplary. Such an embodiment can typically exist with or without the feature(s) mentioned; likewise, those features can be applied to other embodiments of the presently-disclosed subject matter, whether listed in this Summary or not. To avoid excessive repetition, this Summary does not list or suggest all possible combinations of such features.

The presently-disclosed subject matter includes a method of protecting a cell, which involves inhibiting one or more of P2X7 activation associated with or in the cell, inhibiting IRAK1 associated with or in the cell; or inhibiting IRAK4 associated with or in the cell.
In some embodiments, the cell is an RPE cell, a retinal photoreceptor, or a choroidal cell. In some embodiments, the cell is in a subject. In some embodiments, the cell is an RPE cell, and the method also involves identifying a subject for which protection of the RPE cell is desired. In some embodiments, the cell is an RPE cell and the method involves administering the inhibitor to a subject.

In some embodiments of the method, the inhibiting of P2X7 activation includes contacting the cell with a P2X7 activation inhibitor, e.g., P2X7 receptor antagonist A438079.

In some embodiments of the method, inhibiting IRAK1 and/or IRAK4 includes contacting the cell with an IRAK1 and/or IRAK4 inhibitor (e.g., N-(2-Morpholinylethyl)-2-(3-nitrobenzoylamido)-benzimidazole).

In some embodiments, the method can also include inhibiting MyD88 associated with or in the cell; inhibiting IL-18 associated with or in the cell; inhibiting a Dicer polypeptide associated with or in the cell; and/or inhibiting AluRNA associated with or in the cell.

The presently-disclosed subject matter also includes a method of treating macular degeneration, which involves identifying a subject in need of treatment for macular degeneration; and inhibiting P2X7 activation associated with or in a cell of the subject; inhibiting IRAK1 associated with or in a cell of the subject; inhibiting IRAK4 associated with or in a cell of the subject; inhibiting MyD88 associated with or in the cell; inhibiting IL-18 associated with or in the cell; inhibiting an inflammasome associated with or in the cell; increasing levels of a Dicer polypeptide associated with or in the cell; and/or inhibiting AluRNA associated with or in the cell.

In some embodiments of the method, inhibiting MyD88 associated with or in the cell includes contacting the cell with a MyD88 inhibitor. In some embodiments of the method, the inhibiting of P2X7 activation includes contacting the cell with a P2X7 activation inhibitor (e.g., P2X7 receptor antagonist A438079). In some embodiments of the method, the inhibiting IRAK1 and/or IRAK4 includes contacting the cell with an IRAK1 and/or IRAK4 inhibitor (e.g., N-(2-Morpholinylethyl)-2-(3-nitrobenzoylamido)-benzimidazole).

The presently-disclosed subject matter further includes kits useful for practicing methods as disclosed herein. In some embodiments, the kit includes a P2X7 activation inhibitor, packaged together with an IRAK1 and/or IRAK4 inhibitor. In some embodiments, the kit also includes a MyD88 inhibitor, an IL-18 inhibitor, an inflammasome inhibitor, a Dicer polypeptide, and an AluRNA inhibitor.

The presently disclosed subject matter further includes a method of identifying an IRAK1 and/or IRAK4 inhibitor, which involves providing a cultured cell wherein phosphorylated IRAK1 and/or IRAK4 is upregulated; contacting the cell with a candidate compound; and determining whether the candidate compound results in a change in the IRAK1 and/or IRAK4. In some embodiments, the method further includes measuring phosphorylation of IRAK1 and/or IRAK4 by Western Blotting. In some embodiments, the change in the IRAK1 and/or IRAK4 is monitored by measuring cell viability, or measuring the expression of a gene known to be induced by IRAK1 and/or IRAK4 signaling.

**BRIEF DESCRIPTION OF THE DRAWINGS**

The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are used, and the accompanying drawings of which:

FIG. 1. Alu RNA does not activate or function via toll-like receptors (TLRs). (A-E) Subretinal injection of a plasmid coding for Alu RNA (pAlu), but not pNull, induces retinal pigmented epithelium (RPE) degeneration in wild-type mice (A) and in mice deficient in Tlr3 (B) or Tlr7 (C), mice with a mutation (mt) in Unc93b1 (D), which are functionally deficient in TLRs-3,7,9, or deficient in Tlr4 (E). Representative images shown. n=8-12. Fundus photographs, top row; Flat mounts stained for zonula occludens-1 (ZO-1; red), bottom row. Degeneration outlined by blue arrowheads. Scale bars, 20 µm. (F) Stimulation of HEK293 cell lines expressing various TLRs with either of two different Alu RNA sequences does not elicit NF-κB activation as assessed by measuring a secreted alkaline phosphatase reporter under the control of a NF-κB-inducible promoter. Positive (+) controls using TLR-specific ligands activated NF-κB. n=3.

FIG. 2. Alu RNA does not activate several RNA sensors. (A and B) p7SL (a 7SL expression vector) (A) and in vitro synthesized 7SL RNA (B) do not induce RPE degeneration in wild-type mice. (C) RPE degeneration induced by subretinal injection of pAlu in wild-type mice is not blocked by a TLR4 antagonist. (D-E) Mice deficient in Mda5 (D) or Prkr (E) are susceptible to pAlu-induced RPE degeneration. (F) Dephosphorylated (Dep) Alu RNA induces RPE degeneration in wild-type mice just as well as Alu RNA. (G) Mice deficient in Mafs are susceptible to pAlu-induced RPE degeneration. pNull does not induce RPE degeneration in any strain of mice. Degeneration outlined by blue arrowheads. Fundus photographs, top rows; ZO-1 stained (red) RPE flat mounts, bottom rows. n=8 (A-G). (H) A schematic of the innate immune pathways that are not activated by Alu RNA.

FIG. 3. Alu RNA induces RPE degeneration via MyD88. (A) pAlu does not induce RPE degeneration in Myd88−/− mice. (B) pAlu-induced RPE degeneration in wild-type mice is inhibited by a MyD88 homodimerization peptide inhibitor (MyD88i), but not by a control peptide. (C) pAlu-induced RPE degeneration in wild-type mice is inhibited by intravitreal cholesterol-conjugated Myd88 siRNA but not cholesterol-conjugated control siRNA. (D and E) siRNA targeting MyD88 (siMyD88) reduces target gene (D, real-time RT-PCR) and protein (E, western blotting normalized to Vinculin) abundance in mouse RPE cells compared to control siRNA transfection. n=5, *p<0.05 by Student t-test. (F) pAlu does not induce RPE degeneration in Myd88−/− heterozygous (het) mice. (G) Western blot of Alu RNA-induced phosphorylation of IRAK1 and IRAK4 in human RPE cells. Image representative of 3 experiments. (H1) pAlu reduces cell viability of wild-type but not Myd88−/− mouse RPE cells. (I) Loss of human RPE cell viability induced by pAlu is rescued by MyD88i. (J) Subretinal injection of AAV1-BEST1-Cre, but not AAV1-BEST1-GFP, protected Myd88−/− mice from pAlu-induced RPE degeneration. (K) pAlu transfection induces IL-18 secretion from human RPE cells as assessed by ELISA. IL-1β secretion is barely
detectable. n=3, *p<0.05 by Student t-test. (L) Intravitreous administration of recombinant IL-18 induces RPE degeneration in wild-type mice but not in Myd88−/− mice. (M and N) pAlu-induced RPE degeneration in wild-type mice is not rescued by intravitreous administration of IL-1β neutralizing antibody (M) but is rescued by IL-18 neutralizing antibody (N). Representative images shown. n=8-12. Fundus photographs, top row; ZO-1 stained (red) flat mounts, bottom row. Degeneration outlined by blue arrowheads. Scale bars, 20 µm (A-C, F, J, I-L). n=3, *p<0.05 by Student t-test. Error bars represent the SEM of samples within a group (D, E, H, I, K).

FIG. 4. Alu RNA induces RPE degeneration via MyD88, not TRIF or IFNγ. (A) Subretinal administration of pAlu induces RPE degeneration in Ticam1−/− mice. (B) Alu RNA does not induce RPE degeneration in Myd88−/− mice. (C) Subretinal administration of a different Alu expression plasmid (pAlu(2)) also induces RPE degeneration in wild-type but not Myd88−/− mice. (D) Alu RNA does not induce RPE degeneration in MyD88−/− heterozygous (het) mice. (E) MyD88 inhibitory peptide reduces Alu RNA-induced phosphorylation of IRAK1/4, normalized to Vinculin expression. (F) Subretinal injection of AAV1-BEST1-GFP, protects Myd88−/− mice from Alu RNA-induced RPE degeneration. (G) pAlu and Alu RNA induces RPE degeneration in wild-type mice receiving Myd88−/− bone marrow (Myd88−/−→wild-type) but did not do so in Myd88−/− mice receiving wild-type bone marrow (wild-type→Myd88−/−). (H-K) Subretinal administration of pAlu induces RPE degeneration in 1ng−/− (H), 1ng1R1−/− (I), and IIIR1−/− mice (J) but not in IIR1−/− mice (K). pCRELnull administration does not induce RPE degeneration in any strain of mice. Degeneration outlined by blue arrowheads. Fundus photographs, top rows; ZO-1 stained (red) RPE flat mounts, bottom rows. n=8 (A-D, F-K).

FIG. 5. Alu RNA induces RPE degeneration via NLRP3 inflammasome. (A) Western blot of Caspase-1 activation (p20 subunit) by Alu RNA in human RPE cells. (B) Western blot of pAlu-induced IL-18 maturation in RPE cell lysates in wild-type mice impaired by intravitreous Caspase-1 peptide inhibitor. (C) Intravitreous Caspase-1 peptide inhibitor protects wild-type mice from pAlu-induced RPE degeneration. (D) pAlu does not induce RPE degeneration in Casp1−/− mice. (E) pAlu does not induce cytotoxicity in Casp1−/− mouse RPE cells. (F) Alu RNA and LPS+ATP induce formation of PYCARD clusters in human RPE cells transfected with GFP-PYCARD. See also Fig. 6E. (G and H) pAlu does not induce RPE degeneration in Nrps3−/− (G) or Pycard−/− (H) mice. (I) Nrps3−/− and Pycard−/− mouse RPE cells are protected against pAlu-induced loss of cell viability. (J) siRNAs targeting NLRP3 or PYCARD rescued human RPE cells from pAlu-induced cytotoxicity, compared to control siRNA. n=3-4, *p<0.05 by Student t-test (A, B, E, F, I, J). Images representative of 3 experiments. Densitometry values normalized to Vinculin are shown in parentheses (A, B). Fundus photographs, top row; ZO-1 stained (red) flat mounts, bottom row. Degeneration outlined by blue arrowheads. Scale bars, 20 µm (C, D, G, H). Representative images shown.

FIG. 6. Alu RNA induces RPE degeneration via NLRP3 inflammasome activation. Related to Fig. 7 (A) Alu RNA or LPS+ATP induce activation of Caspase-1 in human RPE cells as assessed by increased cleavage of Caspase-3 (green, left panel), a fluorescent-linked peptide substrate, compared to mock treatment. Fluorescence quantification shown in right panel. (B) Western blot of Alu RNA-induced Caspase-1 activation (p20 subunit) in THP-1 and HeLa cells, normalized to Vinculin expression. (C) Caspase-1 inhibitor peptide blocks Alu RNA-induced substrate cleavage in human RPE cells. n=3. (D) Subretinal injection of Alu RNA does not induce RPE degeneration in Casp1−/− mice. (E) Alu RNA or LPS+ATP induce the appearance of a brightly fluorescent cluster of GFP-PYCARD visible in the cytoplasm of human RPE cells. Area in insets shown in higher magnification. Images representative of 3 experiments. (F and G) Subretinal injection of Alu RNA does not induce RPE degeneration in Nrps3−/− (F) or Pycard−/− (G) mice. (H) The abundance of NLRP3 in HEK293 cells transfected with an NLRP3 expression vector and of PYCARD in human RPE cells is reduced by transfection of siRNAs targeting these genes, compared to control (Ctrl) siRNAs. n=3, *p<0.05 compared to Ctrl siRNAs by Student t-test. (I) Alu RNA-induced Caspase-1 activation (p20 subunit) in human RPE cells is unaffected by Myd88 inhibitory peptide, normalized to Vinculin expression. (J) MyD88 inhibitory peptide does not reduce Alu RNA-induced cleavage activity of Caspase-1 in human RPE cells (top panel). Fluorescence quantification (bottom panel). (K) Caspase-1 activation (p20 subunit) in RPE cell lysates of wild-type mice treated with subretinal pAlu administration is unimpaired by intravitreous administration of anti-IL-18 neutralizing antibodies. (L) Alu RNA-induced phosphorylation of IRAK1/4 is reduced by Caspase-1 inhibitory peptide in human RPE cells, normalized to Vinculin expression. Vehicle control injections also do not damage the RPE. Fundus photographs, top rows; ZO-1 stained (red) RPE flat mounts, bottom rows. n=8 (D, F, G). Images representative of 3 experiments (A, B, I, J-L).

FIG. 7. Priming and activation of NLRPs. (A) pAlu induces NLRP3 and IL18 mRNAs in both wild-type and Myd88−/− mouse RPE cells. (B) pAlu induces generation of reactive oxygen species (ROS) in human RPE cells as monitored with the fluorescent probe H2DCFDA (A.U, arbitrary units). (C) The ROS inhibitor APDC blocks pAlu-induced NLRP3 and IL18 mRNAs in human RPE cells. (D) Intravitreous administration of APDC protects wild-type mice from pAlu-induced RPE degeneration. (E) pAlu does not induce RPE degeneration in P2rx7−/− mice. (F) Intravitreous administration of P2X7 receptor antagonist protects wild-type mice from pAlu-induced RPE degeneration. (G) Intravitreous administration of glyburide, but not glipizide, protects wild-type mice from pAlu-induced RPE degeneration. n=3-4, *p<0.05 by Student t-test (A-C). Representative images shown. n=8-12. Fundus photographs, top row; ZO-1 stained (red) flat mounts, bottom row. Degeneration outlined by blue arrowheads. Scale bars, 20 µm (D-G).

FIG. 8. IL-18 and Myd88 induce RPE degeneration via Caspase-3. (A and B) Glycine inhibits human RPE cell death induced by LPS+ATP (A) but not by pAlu (B). (C) Intravitreous administration of recombinant IL-18 induces RPE degeneration in Casp1−/− mice. (D) IL-18-induced activation of Caspase-3 in RPE cell lysates of wild-type mice. (E) IL-18-induced RPE degeneration in wild-type mice is inhibited by intravitreous administration of Caspase-3 inhibitor. (F) Intravitreous administration of Myd88 inhibitory peptide inhibits pAlu-induced cleavage of Caspase-3 in the RPE of wild-type mice. n=3-4 (A, B, D, F), *p<0.05 by Student t-test. Representative images shown. n=8-12. Fundus photographs, top row; ZO-1 stained (red) flat mounts, bottom row. Degeneration outlined by blue arrowheads. Scale bars, 20 µm (C, E).

FIG. 9. DICER1 loss induces cell death via inflammasome. (A) Western blot of Alu RNA-induced Caspase-1 cleavage (p20) inhibited by DICER1 overexpression in human RPE cells. (B and C) DICER1 overexpression...
activates Caspase-1 to mature IL-18. IL-18 signals via MyD88 to phosphorylate IRAK1 and IRAK4, which leads to activation of Caspase-3.

FIG. 13 includes a series of images showing stained flat mounts following intravitreal administration of N-(2-Morpholinyl)ethyl)-2-(3-nitrobenzoylamido)-benzimidazole, an IRAK1/4 inhibitor, in wild-type mice, showing that IRAK1/4 inhibitors protects wild-type mice from Alu RNA-induced RPE degeneration in a dose-dependent manner.

FIG. 14 is a bar graph presenting viability of human RPE cells, and showing that N-(2-Morpholinyl)ethyl)-2-(3-nitrobenzoylamido)-benzimidazole, an IRAK1/4 inhibitor (100 µM), protects human RPE cells from pAlu-induced cytotoxicity.

FIG. 15 is a bar graph presenting viability of human RPE cells, and showing that N-(2-Morpholinyl)ethyl)-2-(3-nitrobenzoylamido)-benzimidazole, an IRAK1/4 inhibitor (100 µM), protects human RPE cells from Alu Alu-induced cytotoxicity.

FIG. 16 is a bar graph showing that MyD88−/− mice have reduced laser-induced choroidal neovascularization as compared to wild-type mice.

FIG. 17 is a bar graph showing that intravitreal injection of a peptide MyD88 inhibitor reduced laser-induced choroidal neovascularization in wild-type mice compared to a control peptide inhibitor.

FIG. 18 is a bar graph showing that intravitreal injection of an siRNA targeting MyD88 (2 µg) reduced laser-induced choroidal neovascularization in wild-type mice at least as well as a neutralizing anti-mouse VEGF antibody, compared to a control siRNA.

DESCRIPTION OF EXEMPLARY EMBODIMENTS

The details of one or more embodiments of the presently-disclosed subject matter are set forth in this document. Modifications to embodiments described in this document, and other embodiments, will be evident to those of ordinary skill in the art after a study of the information provided in this document. The information provided in this document, and particularly the specific details of the described exemplary embodiments, is provided primarily for clearness of understanding and no unnecessary limitations are to be understood therefrom. In case of conflict, the specification of this document, including definitions, will control.

The presently-disclosed subject matter includes methods for inhibiting P2X7 activation and therapeutic and protective uses thereof. Also provided are methods for inhibiting IRAK1 and therapeutic and protective uses thereof. Also provided are methods for identifying inhibitors.

In some embodiments, the presently-disclosed subject matter includes a method of protecting a cell, which involves inhibiting one or more of P2X7 activation associated with or in the cell, inhibiting IRAK1 associated with or in the cell; or inhibiting IRAK4 associated with or in the cell. The cell being protected can be, for example, an RPE cell, a retinal photoreceptor, or a choroidal cell. In some embodiments, the cell is in a subject. In some embodiments, the cell is an RPE cell. In some embodiments, the method includes identifying a subject for which protection of an RPE cell is desired. In some embodiments, the method includes identifying a subject having age-related macular degeneration.

As will be recognized by one or ordinary skill in the art, the term “protecting” or “protection” when used with ref-
ference to a cell or group of cells does not refer to an ability to complete eliminate all instances of cell death. Rather, the skilled artisan will understand that the term “protecting” refers to a reduction in cytotoxicity for a cell or group of cells, or to a reduction in the likelihood of cell death for a cell or group of cells, e.g., Alu-RNA-induced cytotoxicity or cell death. Such reduction can be a reduction by at least about 50%, at least about 75%, at least about 90%, or at least about 95% of the cytotoxicity/cell death of a cellular population. Such reduction can be determined relative to a control, e.g., in the absence of P2X7 activation inhibitor, IRAK-1 inhibitor, and/or IRAK-4 inhibitor.

An inhibitor as described herein can be a polypeptide inhibitor (including oligonucleotide inhibitor), a small molecule inhibitor, or an siRNA inhibitor. It is noted that, the terms “inhibit,” “inhibitor,” or “inhibiting” are not meant to require complete inhibition, but refers to a reduction in signaling. Such reduction can be a reduction by at least about 50%, at least about 75%, at least about 90%, or at least about 95% of the signaling in the absence of the inhibitory effect, e.g., in the absence of a compound that is an inhibitor of the signaling.

In some embodiments of the presently-disclosed subject matter, a method of protecting a cell can include inhibiting of P2X7 activation associated with or in the cell of the subject. In some embodiments, the method further includes identifying a subject in need of treatment for a condition of interest. In some embodiments, inhibiting P2X7 activation includes contacting the cell with a P2X7 activation inhibitor. In some embodiments, contacting the cell with the inhibitor comprises administering the inhibitor to a subject. Such inhibitors can be administered, for example, by topical, intravitreous, subretinal, peribulbar, suprachoroidal, intracapsular, intravenous, intramuscular, or subcutaneous administration, or by inhalational of the inhibitor.

Examples of appropriate P2X7 activation inhibitors include, but are not limited to a P2X7 receptor antagonist (e.g., A438079), an inhibitor of the activation of the P2X7 receptor, or an inhibitor of the expression of P2X7 (including, for example, inhibition of transcription of the P2RX7 gene, and inhibition of translation of a product of the P2RX7 gene, including by use of RNA interference technologies). Examples of inhibitors include, polypeptide inhibitors (which include oligonucleotide inhibitors), small molecule inhibitors, and siRNA inhibitors.

In some embodiments of the presently-disclosed subject matter, a method of protecting a cell can include inhibiting IRAK1 and/or IRAK 4 associated with or in the cell of the subject. In some embodiments, the method further includes identifying a subject in need of treatment for a condition of interest. In some embodiments, inhibiting IRAK1 and/or IRAK 4 includes contacting the cell with a IRAK1 and/or IRAK 4 inhibitor. In some embodiments, contacting the cell with the inhibitor comprises administering the inhibitor to a subject. Such inhibitors can be administered, for example, by topical, intravitreous, subretinal, peribulbar, suprachoroidal, intracapsular, intravenous, intramuscular, or subcutaneous administration, or by inhalational of the inhibitor. Examples of appropriate IRAK1 and/or IRAK 4 inhibitors include, an antagonist, such as a small molecule antagonist, or an inhibitor of the expression of IRAK1, and/or IRAK 4 (including, for example, inhibition of transcription and inhibition of translation, including by use of RNA interference technologies). Examples of inhibitors include, polypeptide inhibitors (which include oligonucleotide inhibitors), small molecule inhibitors, and siRNA inhibitors.

Specific examples of inhibitors that can be used in accordance with the presently-disclosed subject matter include but are not limited to N-(2-Morpholinylethyl)-2-(3-nitrobenzoylamido)-benzimidazole, and other examples are described, for example, in Buckley, G. M, et al., (2008) “IRAK-4 inhibitors. Part III: A series of imidazo[1,2-a]pyridines” Bioorganic & Medicinal Chemistry Letters. 18:656-3660, and other known IRAK inhibitors, including those being developed by Merck (e.g., eshop.emdchemicals.com) and Ligand Pharmaceuticals (e.g., www.ligand.com/irak4-inhibitor).

The methods as described herein can further include inhibiting MyD88 associated with or in a cell of the subject; inhibiting IL-18 associated with or in a cell of the subject; inhibiting an inflammasome associated with or in a cell of the subject; increasing levels of a DICER polypeptide associated with or in a cell of the subject; and/or inhibiting AluRNA associated with or in a cell of the subject. Relevant information and details regarding such additional steps of embodiments of the presently-disclosed subject matter can be found, for example, in U.S. Provisional Patent Application No. 61/543,038; U.S. Provisional Patent Application No. 61/508,867; and International Patent Application No. IPCUS/B/13/8753, each of which is incorporated herein by reference.

In some embodiments, the method of protecting a cell as described herein can be useful for the treatment of a condition of interest, for example, a condition selected from: Geographic atrophy; Macular degeneration; Alzheimer disease; Cryopyrinopathies; Inflammatory Bowel Disease; Keratitis; Gout; Acne vulgaris; Crohn’s disease; Ulcerative colitis; Irritable bowel syndrome; Type 1 diabetes; Type 2 diabetes; Insulin resistance; Obesity; Hemolytic-Uremic Syndrome; Polyoma virus infection; Immune complex renal disease; Acute tubular injury; Lupus nephritis; Familial cold autoinflammatory syndrome; Muckle-Wells syndrome and neonatal onset multisystem inflammatory disease; Chronic infantile neurologic cutaneous and articular autoinflammatory diseases; Renal ischemia-perfusion injury; Glomerulonephritis; Cryoglobulinemia; Systemic vasculitides; IgA nephropathy; Atherosclerosis; HIV/AIDS; Malaria; Helminth parasites; Sepsis and septic shock; Allergic asthma; Hay fever; Chronic obstructive pulmonary disease; Drug-induced lung inflammation; Contact dermatitis; Leprosy; Burkholderia cenocepacia infection; Respiratory syncitial virus infection; Psoriasis; Systemic lupus erythematosus; Scleroderma; Reactive arthritis; Cystic fibrosis; Syphilis, Sjögren’s syndrome; Rheumatoid arthritis; Inflammatory joint disease; Non-alcoholic fatty liver disease; Cardiac surgery (peri-/post-operative inflammation); Acute and chronic organ transplant rejection; Acute and chronic bone marrow transplant rejection; and Tumor angiogenesis. In some embodiments, the condition of interest is geographic atrophy and the cell is an RPE cell. In this regard, a subject having age-related macular degeneration can be treated using methods and compositions as disclosed herein. It is noted that macular degeneration refers to both a dry form of macular degeneration (e.g., geographic atrophy/retinal degeneration), as well as a wet form of macular degeneration (e.g., angiogenesis/blood vessel growth). In this regard, inhibitors as disclosed herein can be useful for treating all forms of macular degeneration. By way of specific example, a MyD88 inhibitor can be used to treat various forms of macular degeneration, and is specifically contemplated for inhibition of choroidal neovascularization.

As used herein, the terms treatment or treating relate to any treatment of a condition of interest, including but not limited to prophylactic treatment and therapeutic treatment.
As such, the terms treatment or treating include, but are not limited to: preventing a condition of interest or the development of a condition of interest; inhibiting the progression of a condition of interest; arresting or preventing the development of a condition of interest; reducing the severity of a condition of interest; ameliorating or relieving symptoms associated with a condition of interest; and causing a regression of the condition of interest or one or more of the symptoms associated with the condition of interest.

As used herein, the term "subject" refers to a target of treatment. The subject of the herein disclosed methods can be a vertebrate, such as a mammal, a fish, a bird, a reptile, or an amphibian. Thus, the subject of the herein disclosed methods can be a human or non-human. Thus, veterinary therapeutic uses are provided in accordance with the presently disclosed subject matter.

The terms "polypeptide", "protein", and "peptide", which are used interchangeably herein, refer to a polymer of the 20 protein amino acids, or amino acid analogs, regardless of its size. The terms "polypeptide fragment" or "fragment", when used in reference to a reference polypeptide, refers to a polypeptide in which amino acid residues are deleted as compared to the reference polypeptide itself, but where the remaining amino acid sequence is usually identical to the corresponding positions in the reference polypeptide. Such deletions can occur at the amino-terminus or carboxy-terminus of the reference polypeptide, from internal portions of the reference polypeptide, or a combination thereof. A fragment can also be a "functional fragment," in which case the fragment retains some or all of the activity of the reference polypeptide as described herein.

The terms "modified amino acid", "modified polypeptide", and "variant" refer to an amino acid sequence that is different from the reference polypeptide by one or more amino acids, e.g., one or more amino acid substitutions. A variant of a reference polypeptide also refers to a variant of a reference polypeptide fragment wherein one or more amino acid substitutions have been made relative to the reference polypeptide. A variant can also be a "functional variant," in which case the variant retains some or all of the activity of the reference protein as described herein. The term functional variant includes a functional variant of a functional fragment of a reference polypeptide.

The presently-disclosed subject matter further includes a kit, useful for practicing the methods as disclosed herein. In some embodiments, the kit can include a P2X7 activation inhibitor, packaged together with an IRAK1 and/or IRAK4 inhibitor. In some embodiments, the kit can also include an IL-18 inhibitor, an inflammasome inhibitor, a DICER polypeptide, and an AluRNA inhibitor.

The presently-disclosed subject matter also includes a method for identifying an IRAK1 and/or IRAK4 inhibitor, including providing a cultured cell wherein phosphorylated IRAK1 and/or IRAK4 is upregulated; contacting the cell with a candidate compound; and determining whether the candidate compound results in a change in the IRAK1 and/or IRAK4. The IRAK1 and/or IRAK4 can be upregulated in the cell, for example, by stimulating the cells with a MyD88 activator (e.g., Alu-RNA, LPS) and measuring phosphorylation (activation) of IRAK1 and/or IRAK4 by Western blotting. The change in the IRAK1 and/or IRAK4 can be monitored, for example, by measuring cell viability, or measuring the expression of a gene known to be induced by IRAK1 and/or IRAK4 signaling.

In certain instances, nucleotides and polypeptides disclosed herein are included in publicly-available databases, such as GENBANK and SWISSPROT. Information including sequences and other information related to such nucleotides and polypeptides included in such publicly-available databases are expressly incorporated by reference.

Unless otherwise indicated or apparent the references to such publicly-available databases are references to the most recent version of the database as of the filing date of this Application.

While the terms herein are believed to be well understood by one of ordinary skill in the art, definitions are set forth to facilitate explanation of the presently-disclosed subject matter.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the presently-disclosed subject matter belongs. Although any methods, devices, and materials similar or equivalent to those disclosed herein can be used in the practice or testing of the presently-disclosed subject matter, representative methods, devices, and materials are now described.

Following long-standing patent law convention, the terms "a", "an", and "the" refer to "one or more" when used in this application, including the claims. Thus, for example, reference to "a cell" includes a plurality of such cells, and so forth.

Unless otherwise indicated, all numbers expressing quantities of ingredients, properties such as reaction conditions, and so forth used in the specification and claims are to be understood as being modified in all instances by the term "about". Accordingly, unless indicated to the contrary, the numerical parameters set forth in this specification and claims are approximations that can vary depending upon the desired properties sought to be obtained by the presently-disclosed subject matter.

As used herein, the term "about," when referring to a value or to an amount of mass, weight, time, volume, concentration or percentage is meant to encompass variations of ±20%, in some embodiments ±10%, in some embodiments ±5%, in some embodiments ±1%, in some embodiments ±0.5%, and in some embodiments ±0.1% from the specified amount, as such variations are appropriate to perform the disclosed method.

As used herein, ranges can be expressed as from "about" one particular value, and/or to "about" another particular value. It is also understood that there are a number of values disclosed herein, and that each value is also herein disclosed as "about" that particular value in addition to the value itself. For example, if the value "10" is disclosed, then "about 10" is also disclosed. It is also understood that each unit between two particular units are also disclosed. For example, if 10 and 15 are disclosed, then 11, 12, 13, and 14 are also disclosed.

The presently-disclosed subject matter is further illustrated by the following specific but non-limiting examples. The following examples may include compilations of data that are representative of data gathered at various times during the course of development and experimentation related to the present invention.

EXAMPLES

Example 1

Subretinal Injection and Imaging.

Subretinal injections (1 µL) in mice were performed using a Pico-Injector (PLI-100, Harvard Apparatus). In vivo transfection of plasmids was achieved using 10% Neuroporter
Culin (1:1,000; Sigma-Aldrich). Caspase-1 activity was quantified by real-time RT-PCR using an Applied Biosystems 7900 HT Fast Real-Time PCR system using the 2-ΔΔCt method.

Protein Abundance and Activity.

Protein abundance was assessed by Western blot analysis using primary antibodies recognizing Caspase-1 (1:500; Invitrogen), pIRAK1 (1:500; Thermo Scientific), pIRAK4 (1:500, Abbamox, Inc), PYCARD (1:200, Santa Cruz Biotechnology), NLRC3 (1:500, Enzo Life Sciences) and Vinculin (1:1,000, Sigma-Aldrich). Caspase-1 activity was visualized using CursapluX E1D2 (Oncoimmunin) reagent according to the manufacturer’s instructions.

Mice.

All animal experiments were approved by institutional review committees and in accordance with the Association for Research in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Visual Research. Wild-type C57BL/6J, Tr7-/-, Tr4/-/- (C57BL/10ScNJ), Tr4+/- (Ticaml Lps2), Ifng_/-, Ifn_8_/-, Il11r_/-, Il18r_/-, P2rx7_/-, Myd88_/-, and Dicer_1_/- mice were purchased from The Jackson Laboratory. Casp1_/-, Nlrp3_/-, and PyCARD_/- mice have been previously described (Kanneganti et al., 2006). Unc93b1_1_/- mice were generously provided by B. A. Beutler via K. Fitzgerald. Mda5_1_/- mice were generously provided by M. Golenbock. Mavs_1_/- mice were generously provided by S. Akira via T. Hawn and D. T. Beutler via K. Fitzgerald. Myd88_1_/- and Tlr7_1_/- mice were generously provided by Z. Chen via K. Fitzgerald. For all procedures, anesthesia was achieved by intraperitoneal injection of 100 mg/kg ketamine hydrochloride (Ft. Dodge Animal Health) and 10 mg/kg xylazine (Phoenix Scientific), and pupils were dilated with topical 1% tropicamide (Alcon Laboratories). Fundus Photography.

Retinal photographs of dilated mouse eyes were taken with a 10x-50 IX camera (Topcon) linked to a digital imaging system (Sony). Human Tissue.

Donor eyes or ocular tissues from patients with geographic atrophy due to AMD or age-matched patients without AMD were obtained from various eye banks. These diagnoses were confirmed by diluted ophthalmic examinaation prior to acquisition of the tissues or eyes. Immunolabeling of human tissue was performed with the rabbit antibody against NLRP3 (1:100, Sigma Aldrich) or rabbit antibody against Caspase-1 (prediluted, AbCam). Isotype IgG was substituted for the primary antibody to assess the specificity of the staining. Bound antibody was detected with biotin-conjugated secondary antibodies, followed by incubation with ABC reagent and visualization by Vector Blue (Vector Laboratories). Levamisole (Vector Laboratories) was used to block endogenous alkaline phosphatase activity. Slides were washed in PBS, counterstained with neutral red (Fisher Scientific), rinsed with deionized water, air dried, and then mounted in Vectamount (Vector Laboratories). Fluorescent labeling of human tissue was performed with the rabbit antibody against PYCARD (1:50, Clone N-15, Santa Cruz Biotechnology). Immunolabeling was visualized by fluorescently conjugated anti-rabbit secondary antibody (Invitrogen). Tissue autofluorescence was quenched by incubating the sections in 0.3% Sudan black (Fisher Scientific). Sections were mounted in Vectashield with DAPI (Vector Laboratories). Mouse RPE/choroid flat mounts were fixed with 4% paraformaldehyde or 100% methanol, stained with rabbit antibodies against human zonula occludens-1 (1:100, Invitrogen) and visualized with Alexa594 (Invitrogen). All images were obtained using the Leica SP-5 or Zeiss Axios Observer Z1 microscopes.

Subretinal Injections.

Subretinal injections (1 µl) in mice were performed using a Pico-Injector (PLI-100, Harvard Apparatus). In vivo transfection of plasmids coding for two different Alu sequences (pAlu) or empty control vector (pNull) (Bennett et al., 2008; Kaneko et al., 2011; Shaikh et al., 1997) was achieved using 10% Neuroporter (Genlantis). AAV1-BEST1-Cre (Alexander and Haswirth, 2008) or AAV1-BEST1-GFP were injected at 1.0x10⁴ pfu/mL and in vitro transcribed Alu RNA was injected at 0.3 mg/mL.

Drug Treatments.

siRNAs formulated in siRNA buffer (20 mM KCl, 0.2 mM MgCl2 in HEPES buffer at pH 7.5; Dharmacon) or phosphate buffered saline (PBS; Sigma-Aldrich); the TLR4 antagonist Ultra Pure Rhodobacter sphaeroides LPS (LPS- RS, InvivoGen), a peptide inhibitor of MyD88 homodimerization IMG-2005 (IMGENEX), control inhibitor (IMGENEX), recombinant IL-18 (Medical & Biological Laboratories), neutralizing rat antibodies against mouse IL-1β (IMGENEX), neutralizing antibodies against mouse IL-1β (Medical & Biological Laboratories), isocontrol IgGs (R&D Systems or eBioscience as appropriate), Caspase-1 inhibitor Z-WEHD-FMK (R&D Systems), Caspase-3 inhibitor Z-DEVD-FMK (R&D Systems), Caspase control inhibitor Z-FA-FMK (R&D Systems), (2R,4R)-APDC (Enzo Life Sciences), GLCipride (Sigma-Aldrich), Glyburide (Sigma-Aldrich), and P2X7 receptor antagonist A438079 (Tocris Bioscience) were dissolved in phosphate buffered saline (PBS; Sigma-Aldrich) or dimethyl sulfoxide (DMSO; Sigma-Aldrich), and injected into the vitreous humor in a total volume of 1 µL with a 33-gauge Exmire microsyringe (Ito Corporation). To assess the effect of MyD88 blockade on pAlu-induced RPE degeneration, 1 µL of cholesterol (chol) conjugated MyD88 siRNA (17+2 nt; 2 µg/µL) was intravitreally injected 1 day after pAlu injection. As a control, Luc siRNA-chol (17+2 nt) was used with identical dosages.

Bone Marrow Chimeras.

Bone marrow transplantation was used to create Myd88_1_/- chimeric mice wherein the genetic deficiency of Myd88 was confined to either circulating cells (Myd88_1_/-→WT) or nonhematopoietic tissue (WT→Myd88_1_/-). Briefly, bone marrows were collected from femur and tibia of congenic WT or Myd88_1_/- donor mice by flushing with...
injected into the tail vein of irradiated donor mice. Two chimera groups were generated: WT→Myd88−/− (WT cells into Myd88−/− mice) and Myd88−/−→WT (Myd88−/− cells into WT mice). 2 months after bone marrow transfer, mice were injected subretinally with Alu RNA, vehicle, pA²u, or pNull, and monitored for RPE degeneration 7 days later.

Real-Time PCR.

Total RNA was extracted from tissues or cells using Trizol reagent (Invitrogen) according to manufacturer’s recommendations, DNase treated and reverse transcribed (QuantiTect, Qiagen). The RT products (cDNA) were amplified by real-time quantitative PCR (Applied Biosystems 7900 HT Fast Real-Time PCR system) with Power SYBR green Master Mix. Oligonucleotide primers specific for human IL1B, human NLRP3, human 18S rRNA, mouse Myd88, mouse Nlrp3, mouse 111T, and mouse 18S rRNA were used. The QPCR cycling conditions were 95°C for 2 min, 95°C for 10 min followed by 40 cycles of a two-step amplification program (95°C for 15 s and 58°C for 1 min). At the end of the amplification, melting curve analysis was applied using the dissociation protocol from the Sequence Detection system to exclude contamination with unspecific PCR products. The PCR products were also confirmed by agarose gel and showed only one specific band of the predicted size. For negative controls, no RT products were used as templates in the QPCR and verified by the absence of gel-detected bands. Relative expressions of target genes were determined by the 2−ΔΔCt method.

miRNA Quantification.

Total RNA containing miRNAs was polyadenylated and reverse transcribed using universal primer using the All-In-One miRNA q-RT-PCR Detection Kit (GeneCopoeia) according to the manufacturer’s specifications using a universal reverse primer in combination with forward primers for: mouse mir-184; mouse mir-221/222; mouse mir-320a; and mouse mir-484. miRNA levels were normalized to levels of U6 snRNA using the 2−ΔΔCt method. Detection was achieved by SYBR green qPCR with the following conditions: 95°C for 10 min followed by 40 cycles of 95°C for 10 s, 60°C for 20 s and 72°C for 20 s. Amplicon specificity was assessed by melt curve analysis and unique bands by agarose gel electrophoresis.

Western Blotting.

Tissues or cells were homogenized in lysis buffer (10 mM Tris base, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 0.5% NP-40, protease and phosphatase inhibitor cocktail (Roche)). Protein concentrations were determined using a Bradford assay kit (Bio-Rad) with bovine serum albumin as a standard. Proteins (40-100 µg) were run on NuPAGE Bis-Tris gels (Invitrogen) and transferred to Immob-Blot PVDF membranes (Bio-Rad). Cells were harvested in hot Laemmli buffer (62.5 mM Tris base, pH 6.8, 2% SDS, 5% 2-Mercaptoethanol, 10% Glyceral, 0.01% Bromophenol Blue). Samples were boiled and run on 4-20% NuPAGE Tris-Glycine gels (Invitrogen). The transferred membranes were blocked for 1 h at RT and incubated with antibodies against human Caspase-1 (1:500; Invitrogen), mouse Caspasel (1:500; MBL), NLRP3 (1:1000; Enzo Life Sciences), PYCARD (1:1000, RayBiotech), phospho-IRAK1 (S376) (1:500, Thermo Scientific), phospho-IRAK4 (T345) (1:500, AbboMax), DICER1 (1:2000; Bethyl), MyD88 (1:1000; Cell Signaling), and mouse IL-18 (1:200; MBL) at 4°C overnight. Protein loading was assessed by immunoblotting using an anti-Vinculin antibody (1:1000; Sigma-Aldrich). The secondary antibodies were used (1:5,000) for 1 h at RT. The signal was visualized by enhanced chemiluminescence (ECL plus) and captured by VisionWorksLS Image Acquisition and Analysis software (Version 6.7.2, UVP, LLC).

Cell Culture.

All cell cultures were maintained at 37°C and 5% CO2. Primary mouse RPE cells were isolated as previously described (Yang et al., 2009) and grown in Dulbecco Modified Eagle Medium (DMEM) supplemented with 20% FBS and standard antibiotics concentrations. Primary human RPE cells were isolated as previously described (Yang et al., 2008) and maintained in DMEM supplemented with 10% FBS and antibiotics. HEK293 cells were maintained in DMEM supplemented with 20% FBS and standard antibiotics concentrations. THP-1 cells were cultured in RPMI 1640 medium supplemented with 10% FBS and antibiotics.

In Vitro Transcription of Alu RNAs.

Two Alu RNAs were synthesized: a 281 nt Alu sequence originating from the cDNA clone TS 103 (Shaikh et al., 1997) and a 302 nt Alu sequence isolated from the RPE of a human eye with geographic atrophy. Linearized plasmids containing these Alu sequences with an adjacent 5′ T7 promoter were subjected to AmpliScribe™ T7-Flash™ Transcription Kit (Epirec™) according to the manufacturer’s instructions. DNase-treated RNA was purified using MEGAclean™ (Ambion), and integrity was monitored by gel electrophoresis. This yields single stranded RNAs that fold into a defined secondary structure identical to Pol III derived transcripts. Where indicated, transcription RNA was dephosphorylated using calf intestine alkaline phosphatase (Invitrogen) and repurified with Phenol:Chloroform:Isoamyl alcohol precipitation.

Transient Transfection.

Human or mouse RPE cells were transfected with pUC19, pAlu, pCDNA3.1/Dicer-FLAG, pCDNA3.1, Alu RNA, NLRP3 siRNA sense, PYCARD siRNA sense, MyD88 siRNA sense, DICER1 antisense oligonucleotide (AS), control (for DICER1) AS, Alu AS, and control (for Alu) AS using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions.

Adenoviral Infection.

Cells were plated at density of 15x10⁴/cm² and after 16 h, at approximately 50% confluence, were infected with AdCre or AdNull (Vector Laboratories) with a multiplicity of infection of 1,000.

Cell Viability.

MTS assays were performed using the CellTiter 96 AQueous One Solution Cell Proliferation Assay (Promega) according to the manufacturer’s instructions. For examining the cytoprotective effect of glycine in Alu RNA induced cell death, human RPE cells were transfected with pNull/pAlu. At 6 h post-transfection the cells were incubated with complete media containing glycine (5 mM) or vehicle, and cell viability was assessed after 24 h. Similarly, human RPE cells primed with LPS (5 µg/ml for 6 h) were treated with ATP (25 µM) in the presence of glycine containing media (5 mM). 30 min post ATP cell viability was assessed as described above.

Caspase-1 Activity.

Caspase-1 activity was visualized by incubating cells with Caspalex1E1 D2 reagent (Oncoimmunin) according to the manufacturer’s instructions. Caspalex1E1D2 signal was quantified reading the fluorescence (excitation 552 nm, emission 580 nm) using a Synergy 4 reader (Biotek). Quantification of fluorescence from images was performed by converting images into grayscale in Adobe Photoshop CS5.
and measuring the integrated density of black and white images using ImageJ software (NIH) (Bogdanovich et al., 2008).

Caspase-3 Activity.

The caspase-3 activity was measured using Caspase-3 Fluorometric Assay (R&D Systems) according to the manufacturer’s instructions.

ROS Activation.

Intracellular ROS was assessed using the ROS-specific probe 2’7’-dichlorodihydrofluorescin diacetate (H₂DCFDA, BioChemica, Fluka). Sub-confluent human RPE cells were transfected with pNull and pAlu. After 24 h cells were loaded for 10 min with 10 µM H₂DCFDA and washed twice with PBS. Fluorescence was recorded in 96-well plate using a Synergy 4 reader (Biotek) using a FITC filter (excitation 485 nm, emission 538 nm).

ELISA.

Secreted cytokine content in conditioned cell culture media was analyzed using the Human IL-1β and IL-18 ELISA Kits (R&D Systems) according to the manufacturer’s instructions.

TLR Screen.

A custom TLR ligand screen was performed by InvivoGen using HEK293 cells over-expressing individual TLR family members coupled with an AP-1/NF-κB reporter system. Cells were stimulated with each of two Alu RNAs synthesized by in vitro transcription, or a TLR-specific positive control ligand.

Statistical Analysis.

Results are expressed as mean±SEM, with p values <0.05 considered statistically significant. Differences between groups were compared by using Mann-Whitney U test or Student t-test, as appropriate, and 2-tailed p values are reported.

Results

Alu RNA does not Activate a Variety of TLRs or RNA Sensors.

Alu RNA has single-stranded (ss) RNA and double-stranded (ds) RNA motifs (Simnett et al., 1991). Therefore, whether Alu RNA induced RPE degeneration in mice deficient in toll-like receptor-3 (TLR3), a dsRNA sensor (Alexeopoulou et al., 2001), or in TLR7, a ssRNA sensor (Diedbold et al., 2004; Heil et al., 2004) was tested. Subretinal administration of a plasmid coding for Alu RNA (pAlu) induced RPE degeneration in Tlr3−/− mice and Tlr7−/− mice just as in wild-type mice (FIGS. 1A-C). It has been shown that 21-nucleotide or longer fully complementary siRNAs can activate TLR3 on RPE cells (Kleinman et al., 2011). The lack of TLR3 activation by Alu RNA can be attributed to its complex structure containing multiple hairpins and bulges that might preclude it from binding TLR3. Neither 7SL RNA, the evolutionary precursor of Alu RNA that also has ssRNA and dsRNA motifs, nor p7SL induced RPE degeneration in wild-type mice (FIGS. 2A and 2B), suggesting that the cytotoxicity of Alu RNA might be due to as yet unclear structural features. pAlu induced RPE degeneration in Unc93b1−/− mutant mice (FIG. 1D), which are devoid of signaling from TLR3, TLR7, and TLR9 (Tabeta et al., 2006), indicating that these nucleic acid sensing TLRs are not activated by Alu RNA redundantly. pAlu administration also induced RPE degeneration in Tlr4−/− mice (FIG. 1E). Corroborating these data, the TLR4 antagonist Rhodobacter sphaeroides LPS (Qureshi et al., 1991) did not inhibit pAlu-induced RPE degeneration in wild-type mice (FIG. 2C). These data dismiss the possibility that TLR4-activating lipopolysaccharide contamination induced the observed RPE cell death. Furthermore, two different in vitro transcribed Alu RNAs (Kaneko et al., 2011) did not activate TLR-2, 3, 4, 5, 7, 8, or 9 in a reporter assay system based in human embryonic kidney 293 cells expressing each of the TLRs (FIG. 1F).

Because Alu RNA induced RPE degeneration independent of TLR activation, whether other dsRNA sensors such as melanoma-differentiation-associated gene 5 (MDA5, Kato et al., 2006) or protein kinase R (PKR, encoded by Prkr, (Yang et al., 1995)) might mediate Alu RNA toxicity was tested. However, pAlu induced RPE degeneration in both Mda5 and Prkrt−/− mice (FIGS. 2D and 2E). The possibility was evaluated that the 5’-triphosphate on in vitro transcribed Alu RNA, which could potentially activate other immune sensors such as retinoic acid inducible gene 1 (RIG-I) or interferon-induced protein with tetratricopeptide repeats 1 (IFIT-1) that can sense this moiety (Hornung et al., 2006; Pitchmair et al., 2011), might be responsible for RPE degeneration. Dephosphorylated Alu RNA induced RPE degeneration in wild-type mice just as well as Alu RNA that had not been subjected to dephosphorylation (FIG. 2F), indicating that the presence of this chemical group is not responsible for the observed cell death in vivo. Indeed, it has been recently shown that a 5’-triphosphate ssRNA that activates RIG-I does not induce RPE degeneration in mice (Kleinman et al., 2011). Supportive of these findings, pAlu induced RPE degeneration in mice deficient in mitochondrial antiviral signaling protein (MAVS) (FIG. 2G), an adaptor protein through which RIG-I and MDA-5 signal (Kumar et al., 2006; Sun et al., 2006). Collectively these data pointed to a novel mechanism of Alu RNA-induced RPE degeneration not mediated by a wide range of canonical RNA sensors.

Alu RNA Cytotoxicity is Mediated Via MyD88 and IL-18.

The potential involvement of TRIF (encoded by Ticam1), an adaptor protein for TLR3 and TLR4 was tested (Hoebel et al., 2003; Yamamoto et al., 2003), and myeloid differentiation primary response protein (MyD88), an adaptor protein for all TLRs except TLR3 was also tested (Akira et al., 2006; Alexeopoulou et al., 2001; Suzuki et al., 2003). Subretinal administration of Alu RNA induced RPE degeneration in Ticam1−/− mice (FIG. 4A), consistent with the findings in Tlr3−/− and Tlr4−/− mice. Unexpectedly however, neither Alu RNA nor two different pAlu plasmids induced RPE degeneration in Myd88−/− mice (FIG. 4B, 4A, 4B, and 4C). To corroborate these genetic findings, pharmacological inhibition of MyD88 was tested. Intravitreous administration of a peptide inhibitor of MyD88 homodimerization (Loiarro et al., 2005) prevented RPE degeneration induced by subretinal administration of Alu RNA in wild-type mice, whereas a control peptide did not impart protection (FIG. 3B). A MyD88-targeting short interfering RNA (siRNA) was tested, which was shorter than 21 nucleotides in length to prevent TLR3 activation and conjugated to cholesterol to enable cell permeation (Kleinman et al., 2008). MyD88 siRNA inhibited RPE degeneration induced by pAlu in wild-type mice, whereas a control siRNA did not do so (FIGS. 3C-3E). MyD88−/− heterozygous mice were protected against Alu RNA-induced RPE degeneration (FIGS. 3F and 4D), corroborating the findings from the siRNA studies that partial knockdown of MyD88 is therapeutically sufficient.

MyD88-mediated signal transduction induced by interleukins leads to recruitment and phosphorylation of the IL-1R-associated kinases IRAK1 and IRAK4 (Cao et al., 1996; Kanakaraj et al., 1999; Suzuki et al., 2003; Suzuki et al., 2002). Alu RNA increased phosphorylation of IRAK1/4...
in human RPE cells (FIG. 3G), supporting the concept that Alu RNA triggers MyD88 signaling. The MyD88 inhibitory peptide reduced Alu RNA-induced phosphorylation of IRAK1/4 in human RPE cells (FIG. 4E), confirming its mechanism of action in this model.

Next it was assessed whether MyD88 activation mediates Alu RNA-induced cell death in human and mouse RPE cell culture systems. In congruence with the in vivo data, pAlu transfection reduced cell viability in wild-type but not Myd88−/− mouse RPE cells (FIG. 3I). The MyD88-inhibitory peptide, but not a control peptide, inhibited cell death in human RPE cells transfected with pAlu (FIG. 3I). Taken together, these data indicate that MyD88 is a critical mediator of Alu RNA-induced RPE degeneration.

MyD88 is generally considered an adaptor of innate immune cells (O’Neill and Bowie, 2007). However, Alu RNA induced cell death via MyD88 in RPE monoculture systems. Therefore, it was determined whether Alu RNA-induced RPE degeneration in mice was also dependent solely on MyD88 activation in RPE cells or whether it required MyD88 activation in innate immune cells. To determine the cell population that is critical for MyD88-dependent RPE cell death, “foxed” MyD88 mice were studied, as well as generated MyD88 bone marrow chimeras. Conditional ablation of MyD88 in the RPE by subretinal injection of AAV1-BEST1-Cre in Myd88−/− mice protected against Alu RNA-induced RPE degeneration (FIGS. 3J and 4I). Consistent with this finding, Alu RNA induced RPE degeneration in wild-type mice receiving Myd88−/− bone marrow but did not do so in Myd88−/− mice receiving wild-type bone marrow (FIG. 4G). Collectively, these results indicate that MyD88 expression in the RPE, and not in circulating immune cells, is critical for Alu RNA-induced RPE degeneration. These findings comport with histopathological studies of human GA tissue that show no infiltration of immune cells in the area of pathology (personal communication, C. A. Curcio, H. E. Grossniklaus, G. S. Hageman, L. V. Johnson).

Although MyD88 is critical in TLR signaling (O’Neill and Bowie, 2007), activation of MyD88 by Alu RNA appeared to be independent of TLR activation. Thus, other potential mechanisms of MyD88 involvement were examined. MyD88 can regulate interferon gamma (IFN-γ) signaling by interacting with IFN-γ receptor 1 (encoded by Ifngr1) (Sun and Ding, 2006). However, pAlu induced RPE degeneration in both Ifngr−/− and Ifngr1−/− mice (FIGS. 4H and 4I). MyD88 is also essential in interleukin-1 (IL-1) signaling (Muzzo et al., 1997). Therefore, it was tested whether IL-1β and the related cytokine IL-18, both of which activate MyD88 (Adachi et al., 1998), were involved in mediating Alu RNA cytotoxicity. Interestingly, whereas Alu RNA overexpression in human RPE cells increased IL-18 secretion, IL-1β secretion was barely detectable (FIG. 3K).

Recombinant IL-18 induced RPE degeneration in wild-type but not Myd88−/− mice (FIG. 3L). A neutralizing antibody against IL-18 protected against pAlu-induced RPE degeneration in wild-type mice, whereas IL-1β neutralization provided no benefit (FIGS. 3M and 3N). Supporting these findings, pAlu induced RPE degeneration in Il1r1−/− mice but not Il1r1−/− mice (FIGS. 4J and 4K). These data indicate that IL-18 is an important effector of Alu RNA-induced cytotoxicity.

Alu RNA activates the NLRP3 inflammasome.

Whether caspase-1 (encoded by Casp1), a protease that can catalyze cleavage of the pro-forms of interleukins to their biologically active forms (Gaynor et al., 1997; Gu et al., 1997; Thornberry et al., 1992), was involved in Alu RNA-induced RPE degeneration was explored. Alu RNA treatment of human RPE cells led to Caspase-1 activation as measured by western blot analysis and by a fluorescent reporter of substrate cleavage (FIGS. 5A and 6A). Indeed, Alu RNA induced Caspase-1 activation in other cell types such as HeLa and THP-1 monocytic cells (FIG. 6B), suggesting that the cytotoxicity of Alu RNA has potentially broad implications in many systems. Intraventricular administration of the Caspase-1-inhibitory peptide Z-WEHD-FMK, but not a control peptide Z-FA-FMK, blocked IL-18 maturation and pAlu-induced RPE degeneration in wild-type mice (FIGS. 5B and 5C). The Caspase-1-inhibitory peptide blocked Alu RNA-induced substrate cleavage in human RPE cells (FIG. 5C), confirming its mechanism of action in this system. These findings were corroborated by the absence of RPE degeneration in Casp1−/− mice treated with Alu RNA or pAlu (FIGS. 5D and 6D). Also, pAlu did not induce cell death in Casp1−/− mouse RPE cells (FIG. 5E).

Caspase-1 can be activated within a multiprotein innate immune complex termed the inflammasome (Tschopp et al., 2003). The best-characterized inflammasome pathway is one that is activated by binding of NLRP3 (nucleotide-binding domain, leucin-rich-containing family, pyrin domain-containing-3) to the caspase-1 adapter apoptosis-associated speck-like protein containing a caspase-recruitment domain (ASC; encoded by PYCARD).

To assess whether Alu RNA induced inflammasome assembly, human RPE cells were transfected with a vector encoding a fusion protein of PYCARD and green fluorescent protein (GFP-PYCARD), which enabled spatial clustering of PYCARD that occurs upon PYCARD activation in cell culture to be optically-monitored (Fernandes-Alnemri et al., 2007). Alu RNA induced the appearance of a brightly fluorescent cluster of GFP-PYCARD visible in the cytoplasm similar to treatment with LPS and AIP, which is known to activate the NLRP3 inflammasome (FIGS. 5F and 6E) (Mariathasan et al., 2006).

Next the functional relevance of NLRP3 and PYCARD to Alu RNA cytotoxicity was tested using genetic and pharmacological inhibition. Neither pAlu nor Alu RNA induced RPE degeneration in either Nlrp3−/− or Pycard−/− mice (FIGS. 5G, 5H, 6F and 6G), demonstrating the critical importance of the inflammasome in transducing the cytotoxicity of Alu RNA. It was also found that pAlu did not induce cell death in Nlrp3−/− or Pycard−/− mouse RPE cells (FIG. 5I). Moreover, knockdown of NLRP3 or PYCARD by siRNAs rescued pAlu-induced human RPE cell death (FIGS. 5J and 6I). These findings provide direct evidence that NLRP3 activation in response to Alu RNA occurs in RPE cells and does not require the presence of other immune cells.

It was determined that IL-18 and MyD88 activation indeed were downstream of Caspase-1 activation by showing (1) that whereas the MyD88 inhibitory peptide reduced Alu RNA-induced phosphorylation of IRAK1/4 in human RPE cells (FIG. 4E), it did not reduce Alu RNA-induced Caspase-1 cleavage or fluorescent substrate cleavage (FIGS. 6I and 6J); (2) that IL-18 neutralizing antibodies did not inhibit Alu RNA-induced Caspase-1 cleavage (FIGS. 6K); and (3) that the Caspase-1 inhibitory peptide reduced Alu RNA-induced phosphorylation of IRAK1/4 (FIG. 6L).

NLRP3 inflammasome function is thought to require two signals, the first of which is termed priming. pAlu induced inflammasome priming as it upregulated both NLRP3 and IL-18 mRNAs. This priming occurred equivalently in both wild-type and Myd88−/− mouse RPE cells (FIG. 7A), further corroborating that MyD88 functions downstream of NLRP3...
DICER1 Loss Induces Cell Death Via Inflammasome. It has been demonstrated that the key role of DICER1 in maintaining RPE cell health (Kaneko et al., 2011). DICER1-cleaved Alu RNA did not induce RPE degeneration in vivo; DICER1 overexpression protected against Alu RNA-induced RPE degeneration; and DICER1 loss-induced RPE degeneration was blocked by antisense oligonucleotides targeting Alu RNA (Kaneko et al., 2011). Also, rescue of DICER1 knockout-induced RPE degeneration by Alu RNA inhibition was not accompanied by restoration of microRNA deficits (Kaneko et al., 2011). Therefore, it was tested whether DICER1 also prevented NLRP3 inflammasome activation by Alu RNA. Alu RNA-induced Caspase-1 activation in human RPE cells, as monitored by western blot analysis and by a fluorescent reporter of substrate cleavage, was inhibited by DICER1 overexpression (FIGS. 6A and 6B). Conversely, Caspase-1 cleavage induced by DICER1 knockdown in human RPE cells, as monitored by immunofluorescence assay, was inhibited by simultaneous antisense-mediated knockdown of Alu RNA (FIGS. 10A and 10B).

In this system, pAlu induced the generation of reactive oxygen species (ROS) (FIG. 7B), a signal for NLRP3 priming (Bauernfeind et al., 2011; Nakahira et al., 2011), and the ROS inhibitor APDC blocked pAlu-induced NLRP3 and IL18 mRNA upregulation (FIG. 7C). Consistent with these data, APDC blocked pAlu-induced RPE degeneration in wild-type mice (FIG. 7D).

NLRP3 inflammasome activation is also known to involve the ATP-gated channel P2X(7) (encoded by P2RX7), whose activation leads to cellular efflux of K+ (Mariathasan et al., 2004). As disclosed herein, P2rx7−/− mice were protected against pAlu-induced RPE degeneration and the P2X receptor antagonist A438079 blocked pAlu-induced RPE degeneration in wild-type mice (FIGS. 7E and 7F). Consistent with these data, pAlu-induced RPE degeneration in wild-type mice was inhibited by gliburide, which functions downstream of P2X7, to block NLRP3 activation (Lamkanfi et al., 2009), but not by the closely related glitizide, which does not block NLRP5 (FIG. 7G).

IL-18 and MyD88 Induces RPE Degeneration Via Caspase-3. The mode of cell death in Alu RNA-induced RPE degeneration mediated via IL-18 activation of MyD88 was sought to be determined. Alu RNA activates Caspase-1, which can trigger pyroptosis, a form of cell death characterized by formation of membrane pores and osmotic lysis (Fink and Cookson, 2006). It was found that the cytoprotective agent glycine, which can attenuate pyroptosis (Fink et al., 2008; Fink and Cookson, 2006; Verhoef et al., 2005), inhibited human RPE cell death induced by LPS+ATP but not by Alu RNA (FIGS. 8A and 8B). Pyroptosis requires Caspase-1 but can proceed independent of IL-18 (Miao et al., 2010). Therefore, the finding that IL-18 induced RPE degeneration in Casp1−/− mice (FIG. 8C), coupled with the lack of rescue by glycine, suggests that Alu RNA-induced RPE degeneration does not occur via pyroptosis.

It was reported earlier that Alu RNA activates Caspase-3 (Kaneko et al., 2011), an executioner protease associated with apoptosis. In wild-type mice, IL-18 induced Caspase-3 activation in the RPE (FIG. 8D), and the Caspase-3 inhibitor Z-DEVD-FMK blocked IL-18-induced RPE degeneration (FIG. 8E). Because IL-18 induces RPE degeneration in mice via MyD88, it was tested whether MyD88 inhibition also blocks Caspase-3 activation. Indeed, the MyD88 inhibitory peptide inhibited Alu RNA-induced Caspase-3 activation in the RPE of wild-type mice (FIG. 8F). Collectively, these data point towards apoptosis as the mode of cell death in Alu RNA-induced RPE degeneration, and are consistent with other systems wherein IL-18 and MyD88 induce apoptosis (Aliprantis et al., 2000; Chandrasekar et al., 2004; Ohtsuki et al., 1997). These findings are also compatible with the observations of Caspase-3 activation (Kaneko et al., 2011) and apoptosis (Duniaef et al., 2002) in RPE cells in human GA.

DISCUSSION
The data presented herein establish a functional role for the subversion of innate immune sensing pathways by repetitive element transcripts in the pathogenesis of GA. Collectively, the findings demonstrate that the NLRP3...
The NLRP3 inflammasome was originally recognized as a sensor of external danger signals such as microbial toxins (Kanneganti et al., 2006; Mariathasan et al., 2004; Mariathasan et al., 2006; Muruve et al., 2008). Subsequently, endogenous crystals, polypeptides, and lipids were reported to activate it in diseases such as gout, atherosclerosis, Alzheimer disease, and Type 2 diabetes (Halle et al., 2008; Masters et al., 2010; Muruve et al., 2008; Vandammasgar et al., 2011; Wen et al., 2011). To the Applicant’s knowledge, Alu RNA is the first endogenous nucleic acid known to activate this immune platform. The findings disclosed herein expand the diversity of endogenous danger signals in chronic human diseases, and comport with the concept that this inflammasome is a sensor of metabolic danger (Schröder et al., 2010).

Dampening inflammasome activation can be essential to limiting the inflammatory response. Pathogens have evolved many strategies to inhibit inflammasome activation (Maranon et al., 2009). Likewise, host autophagy proteins (Nakahira et al., 2011; Saitoh et al., 2008), Type I interferon (Guarda et al., 2011), and T cell contact with macrophages can inhibit this process (Guarda et al., 2009). The finding that DICER1, through its cleavage of retrotransposon transcripts, prevents activation of the NLRP3 inflammasome adds to the repertoire of host inflammasome modulation capabilities and reveal a new facet of how dysregulation of this inflammasome is a sensor of metabolic danger (Schröder et al., 2010).

Although DICER1 levels are important in maintaining RPE cell health by metabolizing Alu RNA, other nucleases also may regulate Alu RNA. For example, Alu is a retrotransposon that can form RNA-DNA replication intermediates, which would be substrates for RNase H. Indeed, RNase H inhibits retrotransposition (Ma and Crouch, 1996), and human enzymes such as LINE-1 (Dhelli et al., 1997; McClure, 1991) contain an RNase H domain. The Argonaute-related PIWI family of nucleases (Park et al., 2004) also contain an RNase H domain, though it is not known whether the human homolog HIL1 degrades retrotransposon intermediates. Other enzymes such as the PIWI-related MIWI in mice also directly cleave retrotransposon RNA (Reuter et al., 2011). Thus, it is likely that DICER1 is one of several mechanisms by which cells regulate retrotransposon expression.

Current clinical programs targeting the inflammasome largely focus on IL-1β; presently there are no IL-18 inhibitors in registered clinical trials. However, the data indicate that IL-18 is more important than IL-1β in mediating RPE cell death in GA (similar to selective IL-1β involvement in a colitis model (Zaki et al., 2010)), pointing to the existence of as yet unknown regulatory mechanisms by which inflammasome activation bifurcates at the level of or just preceding the interleukin effectors. Although Caspase-1 inhibition could be an attractive local therapeutic strategy, caspase inhibitors can promote alternative cell death pathways, possibly limiting their utility (Vandenameele et al., 2006).

MyD88 is best known for transducing TLR signaling initiated by pathogen associated molecular patterns (O’Neill and Bowie, 2007), although recently it has been implicated in human cancers (Ngo et al., 2011; Puente et al., 2011; Rakoff-Nahoum and Medzhitov, 2007). The findings introduce an unexpected new function for MyD88 in effecting death signals from mobile element transcripts that can lead to retinal degeneration and blindness, and raise the possibility that MyD88 could be a central integrator of signals from other non-NLRP3 inflammasomes that also employ Caspase-1 (Schröder and Tschopp, 2010). Since non-canonical activation of MyD88 is a critical checkpoint in RPE degeneration in GA (FIG. 12), it represents an emerging therapeutic target. A potential concern is its important antimicrobial function in mice (O’Neill and Bowie, 2007). However, in contrast to MyD88−/− mice, adult humans with MyD88 deficiency are described to be generally healthy and resistant to a wide variety of microbial pathogens (von Bernuth et al., 2008). MyD88-deficient humans have a narrow susceptibility range to pyogenic bacterial infections, and that too only in early childhood and not adult life (Picard et al., 2010). Moreover, as evident from the siRNA and MyD88 studies, partial inhibition of MyD88 is sufficient to protect against Alu RNA. Localized intravitreal therapy, the current standard of care in most retinal diseases, would further limit the likelihood of adverse infectious outcomes. It is reasonable to foresee development of MyD88 inhibitors for prevention or treatment of GA.

Example 2

It has been have shown that Alu RNA induces RPE degeneration via MyD88 signaling, and that Alu RNA increases phosphorylation of IRAK1 and IRAK4, kinases downstream of MyD88. To determine whether IRAK1/ IRAK4 phosphorylation is critical to Alu RNA-induced RPE degeneration, N-(2-Morpholinylethyl)-2-(3-nitrobenzoylamido)-benzimidazole, an IRAK4 inhibitor, was tested. Indeed it was found that this IRAK4 inhibitor blocked Alu RNA-induced RPE degeneration in wild-type mice in a dose-dependent manner (FIG. 13). With reference to FIG. 13, Alu RNA was injected subretinally in wild-type mice to induce RPE degeneration. Compared to vehicle administration, intravitreal administration of an inhibitor of IRAK1/4 reduced the RPE degeneration induced by Alu RNA in a dose-dependent fashion (1.5-15 µg). With reference to FIG. 14, exposure of human RPE cells to an inhibitor of IRAK1/4 rescued the cell death induced by transfection of pAlu. With reference to FIG. 15, exposure of human RPE cells to an inhibitor of IRAK1/4 rescued the cell death induced by transfection of Alu RNA.

As noted herein, methods disclosed in the present application can be useful for treating all forms of macular degeneration, including the wet form of macular degeneration (e.g., angiogenesis/blood vessel growth). By way of specific example, a MyD88 inhibitor can be used to treat various forms of macular degeneration, and is specifically contemplated for inhibition of choroidal neovascularization.
Relevant data are set forth in FIGS. 16-19. FIG. 16 is a bar graph showing that MyD88−/− mice have reduced laser-induced choroidal neovascularization as compared to wild-type mice. FIG. 17 is a bar graph showing that intravitreal injection of a peptide MyD88 inhibitor reduced laser-induced choroidal neovascularization in wild-type mice compared to a control peptide inhibitor. FIG. 18 is a bar graph showing that intravitreal injection of an siRNA targeting MyD88 (2 µg) reduced laser-induced choroidal neovascularization in wild-type mice at least as well as a neutralizing anti-mouse VEGF antibody, compared to a control siRNA. FIG. 19 is a bar graph showing that intravitreal injection of an inhibitor of IRAK1/4 reduced laser-induced choroidal neovascularization in wild-type mice compared to vehicle.

Throughout this document, various references are mentioned. All such references are incorporated herein by reference, including the references set forth in the following list:

REFERENCES


What is claimed is:

1. A method of treating dry macular degeneration, comprising:
   (a) identifying a subject in need of treatment for dry macular degeneration; and
   (b) administering a composition to the subject the composition binding with MyD88 in an retinal pigmented epithelium (RPE) cell of the subject to inhibit the MyD88; with IL-18 in an RPE cell of the subject to inhibit the IL-18; or with NLRP3 inflammasome, or Caspase-1 in an RPE cell of the subject to inhibit the inflammasome.

2. The method of claim 1, wherein the composition comprises MyD88 siRNA.

* * * * *